Product Images Lenalidomide

Survival probability and progression-free survival in months are presented in the given text. There is also a mention of the number of subjects at risk. However, due to a lack of clarity in the text, it is challenging to provide a specific description of what the text refers to.*

This is a statistical report comparing the effectiveness of two treatments, Lenalidomide and Placebo, in terms of progression-free survival over a period of 108 months. The report presents the HR (95% CI) for the two treatments, as well as the KM median for Lenalidomide and Placebo. The number of subjects at risk and PFS events are also presented.*

This appears to be a statistical analysis of the results of a clinical trial comparing the effectiveness of Lenalidomide vs placebo in terms of progression-free survival (PFS) among a group of test subjects. The analysis includes KM median and HR (hazard ratio) values with corresponding confidence intervals, as well as the number of subjects at risk for PFS events.*

The text shows a graph that displays the percentage of subjects at different levels (100%, 75%, 50%, and 25%). However, without additional information, it is not clear what the graph measures or represents. The text also shows a result of a study using Lenalidomide/Dex and reports the Hazard Ratio (HR) and Log Rank p (a statistical test) for time to progression in months.*

This is a prescription drug with the name Lenalidomide produced by Cipla. Each capsule contains 5 mg of lenalidomide. The drug has a warning on the pack that there is a potential for human birth defects. The pharmacist is instructed to dispense the accompanying medication guide to the patient. The text advises anyone with a prescription to refer to the prescribing information for dosing and administration details. The medicine should be stored at 20°C to 25°C. The manufacturer is Cipla Ltd. The drug was manufactured for Cipla USA, Inc. in Warren, NJ. The date of the text is 3/09/2021.*

This is a label for Lenalidomide, a prescription medication containing 10 mg per capsule. It must be stored between 15°C to 20°C and should only be dispensed to patients with a prescription. The label provides details about the manufacturer, Cipla Ltd., as well as the associated risks for potential birth defects. There are 28 capsules in the package and the pharmacist is advised to dispense a medication guide to each patient.*

This is a medication label for Lenalidomide capsules, with a warning about the potential for human birth defects. The pharmacist is advised to dispense a medication guide to each patient. Each capsule contains 15 mg of lenalidomide, and the prescribing information should be consulted for dosing and administration. The medication should be stored at 20°C to 25°C and between 15°C to 30°C. The label includes information about the manufacturer and the location of manufacture, as well as a barcode and a SAP code.*

This is a warning label for Lenalidomide capsules containing 25mg of the drug. The pharmacist is instructed to dispense with the accompanying medication guide for each patient due to the potential risk of birth defects. The recommended storage temperature is between 20°C to 25°C (66°F to 77°F). The medicine was manufactured by Cipla Ltd. and is intended for use by Clpia USA, Inc. This label was created on 23/09/2021.*